DNA topoisomerase 2-beta
Details
- Name
- DNA topoisomerase 2-beta
- Synonyms
- 5.99.1.3
- DNA topoisomerase II, beta isozyme
- Gene Name
- TOP2B
- Organism
- Humans
- Amino acid sequence
>lcl|BSEQ0004762|DNA topoisomerase 2-beta MAKSGGCGAGAGVGGGNGALTWVTLFDQNNAAKKEESETANKNDSSKKLSVERVYQKKTQ LEHILLRPDTYIGSVEPLTQFMWVYDEDVGMNCREVTFVPGLYKIFDEILVNAADNKQRD KNMTCIKVSIDPESNIISIWNNGKGIPVVEHKVEKVYVPALIFGQLLTSSNYDDDEKKVT GGRNGYGAKLCNIFSTKFTVETACKEYKHSFKQTWMNNMMKTSEAKIKHFDGEDYTCITF QPDLSKFKMEKLDKDIVALMTRRAYDLAGSCRGVKVMFNGKKLPVNGFRSYVDLYVKDKL DETGVALKVIHELANERWDVCLTLSEKGFQQISFVNSIATTKGGRHVDYVVDQVVGKLIE VVKKKNKAGVSVKPFQVKNHIWVFINCLIENPTFDSQTKENMTLQPKSFGSKCQLSEKFF KAASNCGIVESILNWVKFKAQTQLNKKCSSVKYSKIKGIPKLDDANDAGGKHSLECTLIL TEGDSAKSLAVSGLGVIGRDRYGVFPLRGKILNVREASHKQIMENAEINNIIKIVGLQYK KSYDDAESLKTLRYGKIMIMTDQDQDGSHIKGLLINFIHHNWPSLLKHGFLEEFITPIVK ASKNKQELSFYSIPEFDEWKKHIENQKAWKIKYYKGLGTSTAKEAKEYFADMERHRILFR YAGPEDDAAITLAFSKKKIDDRKEWLTNFMEDRRQRRLHGLPEQFLYGTATKHLTYNDFI NKELILFSNSDNERSIPSLVDGFKPGQRKVLFTCFKRNDKREVKVAQLAGSVAEMSAYHH GEQALMMTIVNLAQNFVGSNNINLLQPIGQFGTRLHGGKDAASPRYIFTMLSTLARLLFP AVDDNLLKFLYDDNQRVEPEWYIPIIPMVLINGAEGIGTGWACKLPNYDAREIVNNVRRM LDGLDPHPMLPNYKNFKGTIQELGQNQYAVSGEIFVVDRNTVEITELPVRTWTQVYKEQV LEPMLNGTDKTPALISDYKEYHTDTTVKFVVKMTEEKLAQAEAAGLHKVFKLQTTLTCNS MVLFDHMGCLKKYETVQDILKEFFDLRLSYYGLRKEWLVGMLGAESTKLNNQARFILEKI QGKITIENRSKKDLIQMLVQRGYESDPVKAWKEAQEKAAEEDETQNQHDDSSSDSGTPSG PDFNYILNMSLWSLTKEKVEELIKQRDAKGREVNDLKRKSPSDLWKEDLAAFVEELDKVE SQEREDVLAGMSGKAIKGKVGKPKVKKLQLEETMPSPYGRRIIPEITAMKADASKKLLKK KKGDLDTAAVKVEFDEEFSGAPVEGAGEEALTPSVPINKGPKPKREKKEPGTRVRKTPTS SGKPSAKKVKKRNPWSDDESKSESDLEETEPVVIPRDSLLRRAAAERPKYTFDFSEEEDD DADDDDDDNNDLEELKVKASPITNDGEDEFVPSDGLDKDEYTFSPGKSKATPEKSLHDKK SQDFGNLFSFPSYSQKSEDDSAKFDSNEEDSASVFSPSFGLKQTDKVPSKTVAAKKGKPS SDTVPKPKRAPKQKKVVEAVNSDSDSEFGIPKKTTTPKGKGRGAKKRKASGSENEGDYNP GRKTSKTTSKKPKKTSFDQDSDVDIFPSDFPTEPPSLPRTGRARKEVKYFAESDEEEDDV DFAMFN
- Number of residues
- 1626
- Molecular Weight
- 183265.825
- Theoretical pI
- 8.16
- GO Classification
- FunctionsATP binding / chromatin binding / DNA binding, bending / DNA topoisomerase type II (ATP-hydrolyzing) activity / enzyme binding / histone deacetylase binding / metal ion binding / protein C-terminus binding / protein heterodimerization activity / protein kinase C bindingProcessesaxonogenesis / DNA topological change / DNA unwinding involved in DNA replication / forebrain development / mitotic DNA integrity checkpoint / mitotic recombination / neuron migration / resolution of meiotic recombination intermediates / sister chromatid segregationComponentscytoplasm / cytosol / DNA topoisomerase complex (ATP-hydrolyzing) / nucleoplasm / nucleus
- General Function
- Protein kinase c binding
- Specific Function
- Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks.
- Pfam Domain Function
- Transmembrane Regions
- Not Available
- Cellular Location
- Cytoplasm
- Gene sequence
>lcl|BSEQ0020612|DNA topoisomerase 2-beta (TOP2B) ATGGCCAAGTCGGGTGGCTGCGGCGCGGGAGCCGGCGTGGGCGGCGGCAACGGGGCACTG ACCTGGGTGAACAATGCTGCAAAAAAAGAAGAGTCAGAAACTGCCAACAAAAATGATTCT TCAAAGAAGTTGTCTGTTGAGAGAGTGTATCAGAAGAAGACACAACTTGAACACATTCTT CTTCGTCCTGATACATATATTGGGTCAGTGGAGCCATTGACGCAGTTCATGTGGGTGTAT GATGAAGATGTAGGAATGAATTGCAGGGAGGTTACCTTTGTGCCAGGTTTATACAAGATC TTTGATGAAATTTTGGTTAATGCTGCTGACAATAAACAGAGGGATAAGAACATGACTTGT ATTAAAGTTTCTATTGATCCTGAATCTAACATTATAAGCATTTGGAATAATGGGAAAGGC ATTCCAGTAGTAGAACACAAGGTAGAGAAAGTTTATGTTCCTGCTTTAATTTTTGGACAG CTTTTAACATCCAGTAACTATGATGATGATGAGAAAAAAGTTACAGGTGGTCGTAATGGT TATGGTGCAAAACTTTGTAATATTTTCAGTACAAAGTTTACAGTAGAAACAGCTTGCAAA GAATACAAACACAGTTTTAAGCAGACATGGATGAATAATATGATGAAGACTTCTGAAGCC AAAATTAAACATTTTGATGGTGAAGATTACACATGCATAACATTCCAACCAGATCTGTCC AAATTTAAGATGGAAAAACTTGACAAGGATATTGTGGCCCTCATGACTAGAAGGGCATAT GATTTGGCTGGTTCGTGTAGAGGGGTCAAGGTCATGTTTAATGGAAAGAAATTGCCTGTA AATGGATTTCGCAGTTATGTAGATCTTTATGTGAAAGACAAATTGGATGAAACTGGGGTG GCCCTGAAAGTTATTCATGAGCTTGCAAATGAAAGATGGGATGTTTGTCTCACATTGAGT GAAAAAGGATTCCAGCAAATCAGCTTTGTAAATAGTATTGCAACTACAAAAGGTGGACGG CACGTGGATTATGTGGTAGATCAAGTTGTTGGTAAACTGATTGAAGTAGTTAAGAAAAAG AACAAAGCTGGTGTATCAGTGAAACCATTTCAAGTAAAAAACCATATATGGGTTTTTATT AATTGCCTTATTGAAAATCCAACTTTTGATTCTCAGACTAAGGAAAACATGACTCTGCAG CCCAAAAGTTTTGGGTCTAAATGCCAGCTGTCAGAAAAATTTTTTAAAGCAGCCTCTAAT TGTGGCATTGTAGAAAGTATCCTGAACTGGGTGAAATTTAAGGCTCAGACTCAGCTGAAT AAGAAGTGTTCATCAGTAAAATACAGTAAAATCAAAGGTATTCCCAAACTGGATGATGCT AATGATGCTGGTGGTAAACATTCCCTGGAGTGTACACTGATATTAACAGAGGGAGACTCT GCCAAATCACTGGCTGTGTCTGGATTAGGTGTGATTGGACGAGACAGATACGGAGTTTTT CCACTCAGGGGCAAAATTCTTAATGTACGGGAAGCTTCTCATAAACAGATCATGGAAAAT GCTGAAATAAATAATATTATTAAAATAGTTGGTCTACAATATAAGAAAAGTTACGATGAT GCAGAATCTCTGAAAACCTTACGCTATGGAAAGATTATGATTATGACCGATCAGGATCAA GATGGTTCTCACATAAAAGGCCTGCTTATTAATTTCATCCATCACAATTGGCCATCACTT TTGAAGCATGGTTTTCTTGAAGAGTTCATTACTCCTATTGTAAAGGCAAGCAAAAATAAG CAGGAACTTTCCTTCTACAGTATTCCTGAATTTGACGAATGGAAAAAACATATAGAAAAC CAGAAAGCCTGGAAAATAAAGTACTATAAAGGATTGGGTACTAGTACAGCTAAAGAAGCA AAGGAATATTTTGCTGATATGGAAAGGCATCGCATCTTGTTTAGATATGCTGGTCCTGAA GATGATGCTGCCATTACCTTGGCATTTAGTAAGAAGAAGATTGATGACAGAAAAGAATGG TTAACAAATTTTATGGAAGACCGGAGACAGCGTAGGCTACATGGCTTACCAGAGCAATTT TTATATGGTACTGCAACAAAGCATTTGACTTATAATGATTTCATCAACAAGGAATTGATT CTCTTCTCAAACTCAGACAATGAAAGATCTATACCATCTCTTGTTGATGGCTTTAAACCT GGCCAGCGGAAAGTTTTATTTACCTGTTTCAAGAGGAATGATAAACGTGAAGTAAAAGTT GCCCAGTTGGCTGGCTCTGTTGCTGAGATGTCGGCTTATCATCATGGAGAACAAGCATTG ATGATGACTATTGTGAATTTGGCTCAGAACTTTGTGGGAAGTAACAACATTAACTTGCTT CAGCCTATTGGTCAGTTTGGAACTCGGCTTCATGGTGGCAAAGATGCTGCAAGCCCTCGT TATATTTTCACAATGTTAAGCACTTTAGCAAGGCTACTTTTTCCTGCTGTGGATGACAAC CTCCTTAAGTTCCTTTATGATGATAATCAACGTGTAGAGCCTGAGTGGTATATTCCTATA ATTCCCATGGTTTTAATAAATGGTGCTGAGGGCATTGGTACTGGATGGGCTTGTAAACTA CCCAACTATGATGCTAGGGAAATTGTGAACAATGTCAGACGAATGCTAGATGGCCTGGAT CCTCATCCCATGCTTCCAAACTACAAAAACTTTAAAGGCACGATTCAAGAACTTGGTCAA AACCAGTATGCAGTCAGTGGTGAAATATTTGTAGTGGACAGAAACACAGTAGAAATTACA GAGCTTCCAGTTAGAACTTGGACACAGGTATATAAAGAACAGGTTTTAGAACCTATGCTA AATGGAACAGATAAAACACCAGCATTAATTTCTGATTATAAAGAATATCATACTGACACA ACTGTGAAATTTGTGGTGAAAATGACTGAAGAGAAACTAGCACAAGCAGAAGCTGCTGGA CTGCATAAAGTTTTTAAACTTCAAACTACTCTTACTTGTAATTCCATGGTACTTTTTGAT CATATGGGATGTCTGAAGAAATATGAAACTGTGCAAGACATTCTGAAAGAATTCTTTGAT TTACGATTAAGTTATTACGGTTTACGTAAGGAGTGGCTTGTGGGAATGTTGGGAGCAGAA TCTACAAAGCTTAACAATCAAGCCCGTTTCATTTTAGAGAAGATACAAGGGAAAATTACT ATAGAGAATAGGTCAAAGAAAGATTTGATTCAAATGTTAGTCCAGAGAGGTTATGAATCT GACCCAGTGAAAGCCTGGAAAGAAGCACAAGAAAAGGCAGCAGAAGAGGATGAAACACAA AACCAGCATGATGATAGTTCCTCCGATTCAGGAACTCCTTCAGGCCCAGATTTTAATTAT ATTTTAAATATGTCTCTGTGGTCTCTTACTAAAGAAAAAGTTGAAGAACTGATTAAACAG AGAGATGCAAAAGGGCGAGAGGTCAATGATCTTAAAAGAAAATCTCCTTCAGATCTTTGG AAAGAGGATTTAGCGGCATTTGTTGAAGAACTGGATAAAGTGGAATCTCAAGAACGAGAA GATGTTCTGGCTGGAATGTCTGGAAAAGCAATTAAAGGTAAAGTTGGCAAACCTAAGGTG AAGAAACTCCAGTTGGAAGAGACAATGCCCTCACCTTATGGCAGAAGAATAATTCCTGAA ATTACAGCTATGAAGGCAGATGCCAGCAAAAAGTTGCTGAAGAAGAAGAAGGGTGATCTT GATACTGCAGCAGTAAAAGTGGAATTTGATGAAGAATTCAGTGGAGCACCAGTAGAAGGT GCAGGAGAAGAGGCATTGACTCCATCAGTTCCTATAAATAAAGGTCCCAAACCTAAGAGG GAGAAGAAGGAGCCTGGTACCAGAGTGAGAAAAACACCTACATCATCTGGTAAACCTAGT GCAAAGAAAGTGAAGAAACGGAATCCTTGGTCAGATGATGAATCCAAGTCAGAAAGTGAT TTGGAAGAAACAGAACCTGTGGTTATTCCAAGAGATTCTTTGCTTAGGAGAGCAGCAGCC GAAAGACCTAAATACACATTTGATTTCTCAGAAGAAGAGGATGATGATGCTGATGATGAT GATGATGACAATAATGATTTAGAGGAATTGAAAGTTAAAGCATCTCCCATAACAAATGAT GGGGAAGATGAATTTGTTCCTTCAGATGGGTTAGATAAAGATGAATATACATTTTCACCA GGCAAATCAAAAGCCACTCCAGAAAAATCTTTGCATGACAAAAAAAGTCAGGATTTTGGA AATCTCTTCTCATTTCCTTCATATTCTCAGAAGTCAGAAGATGATTCAGCTAAATTTGAC AGTAATGAAGAAGATTCTGCTTCTGTTTTTTCACCATCATTTGGTCTGAAACAGACAGAT AAAGTTCCAAGTAAAACGGTAGCTGCTAAAAAGGGAAAACCGTCTTCAGATACAGTCCCT AAGCCCAAGAGAGCCCCAAAACAGAAGAAAGTAGTAGAGGCTGTAAACTCTGACTCGGAT TCAGAATTTGGCATTCCAAAGAAGACTACAACACCAAAAGGTAAAGGCCGAGGGGCAAAG AAAAGGAAAGCATCTGGCTCTGAAAATGAAGGCGATTATAACCCTGGCAGGAAAACATCC AAAACAACAAGCAAGAAACCGAAGAAGACATCTTTTGATCAGGATTCAGATGTGGACATC TTCCCCTCAGACTTCCCTACTGAGCCACCTTCTCTGCCACGAACCGGTCGGGCTAGGAAA GAAGTAAAATATTTTGCAGAGTCTGATGAAGAAGAAGATGATGTTGATTTTGCAATGTTT AATTAA
- Chromosome Location
- 3
- Locus
- 3p24
- External Identifiers
Resource Link UniProtKB ID Q02880 UniProtKB Entry Name TOP2B_HUMAN GenBank Gene ID X68060 GenAtlas ID TOP2B HGNC ID HGNC:11990 - General References
- Jenkins JR, Ayton P, Jones T, Davies SL, Simmons DL, Harris AL, Sheer D, Hickson ID: Isolation of cDNA clones encoding the beta isozyme of human DNA topoisomerase II and localisation of the gene to chromosome 3p24. Nucleic Acids Res. 1992 Nov 11;20(21):5587-92. [Article]
- Austin CA, Sng JH, Patel S, Fisher LM: Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases. Biochim Biophys Acta. 1993 Mar 20;1172(3):283-91. [Article]
- Chung TD, Drake FH, Tan KB, Per SR, Crooke ST, Mirabelli CK: Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci U S A. 1989 Dec;86(23):9431-5. [Article]
- Sng JH, Heaton VJ, Bell M, Maini P, Austin CA, Fisher LM: Molecular cloning and characterization of the human topoisomerase IIalpha and IIbeta genes: evidence for isoform evolution through gene duplication. Biochim Biophys Acta. 1999 Mar 19;1444(3):395-406. [Article]
- Austin CA, Fisher LM: Isolation and characterization of a human cDNA clone encoding a novel DNA topoisomerase II homologue from HeLa cells. FEBS Lett. 1990 Jun 18;266(1-2):115-7. [Article]
- Yuwen H, Hsia CC, Nakashima Y, Evangelista A, Tabor E: Binding of wild-type p53 by topoisomerase II and overexpression of topoisomerase II in human hepatocellular carcinoma. Biochem Biophys Res Commun. 1997 May 8;234(1):194-7. [Article]
- Davies SL, Jenkins JR, Hickson ID: Human cells express two differentially spliced forms of topoisomerase II beta mRNA. Nucleic Acids Res. 1993 Aug 11;21(16):3719-23. [Article]
- West KL, Meczes EL, Thorn R, Turnbull RM, Marshall R, Austin CA: Mutagenesis of E477 or K505 in the B' domain of human topoisomerase II beta increases the requirement for magnesium ions during strand passage. Biochemistry. 2000 Feb 15;39(6):1223-33. [Article]
- Mirski SE, Bielawski JC, Cole SP: Identification of functional nuclear export sequences in human topoisomerase IIalpha and beta. Biochem Biophys Res Commun. 2003 Jul 11;306(4):905-11. [Article]
- Olsen JV, Blagoev B, Gnad F, Macek B, Kumar C, Mortensen P, Mann M: Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. Cell. 2006 Nov 3;127(3):635-48. [Article]
- Beausoleil SA, Villen J, Gerber SA, Rush J, Gygi SP: A probability-based approach for high-throughput protein phosphorylation analysis and site localization. Nat Biotechnol. 2006 Oct;24(10):1285-92. Epub 2006 Sep 10. [Article]
- Giorgianni F, Zhao Y, Desiderio DM, Beranova-Giorgianni S: Toward a global characterization of the phosphoproteome in prostate cancer cells: identification of phosphoproteins in the LNCaP cell line. Electrophoresis. 2007 Jun;28(12):2027-34. [Article]
- Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER 3rd, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, Shiloh Y, Gygi SP, Elledge SJ: ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007 May 25;316(5828):1160-6. [Article]
- Cantin GT, Yi W, Lu B, Park SK, Xu T, Lee JD, Yates JR 3rd: Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient phosphoproteomic analysis. J Proteome Res. 2008 Mar;7(3):1346-51. doi: 10.1021/pr0705441. Epub 2008 Jan 26. [Article]
- Carrascal M, Ovelleiro D, Casas V, Gay M, Abian J: Phosphorylation analysis of primary human T lymphocytes using sequential IMAC and titanium oxide enrichment. J Proteome Res. 2008 Dec;7(12):5167-76. [Article]
- Dephoure N, Zhou C, Villen J, Beausoleil SA, Bakalarski CE, Elledge SJ, Gygi SP: A quantitative atlas of mitotic phosphorylation. Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10762-7. doi: 10.1073/pnas.0805139105. Epub 2008 Jul 31. [Article]
- Gauci S, Helbig AO, Slijper M, Krijgsveld J, Heck AJ, Mohammed S: Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem. 2009 Jun 1;81(11):4493-501. doi: 10.1021/ac9004309. [Article]
- Mayya V, Lundgren DH, Hwang SI, Rezaul K, Wu L, Eng JK, Rodionov V, Han DK: Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions. Sci Signal. 2009 Aug 18;2(84):ra46. doi: 10.1126/scisignal.2000007. [Article]
- Olsen JV, Vermeulen M, Santamaria A, Kumar C, Miller ML, Jensen LJ, Gnad F, Cox J, Jensen TS, Nigg EA, Brunak S, Mann M: Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal. 2010 Jan 12;3(104):ra3. doi: 10.1126/scisignal.2000475. [Article]
- Burkard TR, Planyavsky M, Kaupe I, Breitwieser FP, Burckstummer T, Bennett KL, Superti-Furga G, Colinge J: Initial characterization of the human central proteome. BMC Syst Biol. 2011 Jan 26;5:17. doi: 10.1186/1752-0509-5-17. [Article]
- Rigbolt KT, Prokhorova TA, Akimov V, Henningsen J, Johansen PT, Kratchmarova I, Kassem M, Mann M, Olsen JV, Blagoev B: System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. Sci Signal. 2011 Mar 15;4(164):rs3. doi: 10.1126/scisignal.2001570. [Article]
- Bian Y, Song C, Cheng K, Dong M, Wang F, Huang J, Sun D, Wang L, Ye M, Zou H: An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome. J Proteomics. 2014 Jan 16;96:253-62. doi: 10.1016/j.jprot.2013.11.014. Epub 2013 Nov 22. [Article]
- Hendriks IA, D'Souza RC, Yang B, Verlaan-de Vries M, Mann M, Vertegaal AC: Uncovering global SUMOylation signaling networks in a site-specific manner. Nat Struct Mol Biol. 2014 Oct;21(10):927-36. doi: 10.1038/nsmb.2890. Epub 2014 Sep 14. [Article]
- Wu CC, Li TK, Farh L, Lin LY, Lin TS, Yu YJ, Yen TJ, Chiang CW, Chan NL: Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide. Science. 2011 Jul 22;333(6041):459-62. doi: 10.1126/science.1204117. [Article]
Drug Relations
- Drug Relations
DrugBank ID Name Drug group Pharmacological action? Actions Details DB04395 Phosphoaminophosphonic Acid-Adenylate Ester experimental unknown Details DB05022 Amonafide investigational unknown Details DB05488 Technetium Tc-99m ciprofloxacin investigational unknown Details DB06042 ZEN-012 investigational unknown Details DB06362 Becatecarin investigational unknown Details DB06421 Declopramide investigational unknown Details DB00694 Daunorubicin approved yes inhibitor Details DB08651 3'-THIO-THYMIDINE-5'-PHOSPHATE experimental unknown Details DB00380 Dexrazoxane approved, withdrawn unknown Details DB00773 Etoposide approved no inhibitor Details DB00997 Doxorubicin approved, investigational yes inhibitor Details DB00970 Dactinomycin approved, investigational unknown inhibitor Details DB01059 Norfloxacin approved unknown inhibitor Details